• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

69.42 -5.03 (-6.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,463,723
Open 74.09
Bid (Size) 65.02 (100)
Ask (Size) 71.00 (100)
Prev. Close 74.45
Today's Range 69.17 - 76.00
52wk Range 12.29 - 76.00
Shares Outstanding 101,192,921
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+127.0%
+127.0%
1 Month
+45.9%
+45.9%
3 Month
+112.0%
+112.0%
6 Month
+191.9%
+191.9%
1 Year
+359.4%
+359.4%

More News

Read More
News headline image
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
April 13, 2026
Via Chartmill
News headline image
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
April 10, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗
April 08, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
March 18, 2026
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
March 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
March 16, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
March 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
February 23, 2026
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 19, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
February 18, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
January 12, 2026
From Spyre Therapeutics, Inc.
Via GlobeNewswire
Spyre Therapeutics' CEO Sells 15,000 Shares ↗
January 11, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 04, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
November 04, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
October 29, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire
News headline image
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
October 24, 2025
From Spyre Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 69.42
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 05/01/26 04:00 PM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 7.02B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap